1. Mechanisms by which crystalline mannitol improves the reconstitution time of high concentration lyophilized protein formulations;Kulkarni;Eur. J. Pharm. Biopharm.,2018
2. Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies;Cao;Eur. J. Pharm. Biopharm.,2013
3. Cimzia® (certolizumab pegol), For injection, subcutaneous [Labeling]. UCB, Inc. [cited 2017 September]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf.
4. Xolair® (omalizumab), For injection, subcutaneous [Labeling]. Novartis Pharmaceuticals Corporation and Genentech, Inc. [cited 2019 September]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103976s5102lbl.pdf.
5. Cosentyx® (secukinumab), For injection, subcutaneous [Labeling]. Novartis Pharmaceuticals Corporation. [cited 2017 September]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125504s000lbl.pdf.